Expression of lncRNA FGD5-AS1 correlates with poor prognosis in melanoma patients
Expression of lncRNA FGD5-AS1 correlates with poor prognosis in melanoma patients
复制标题
DOI：
10.1002/jgm.3278
复制
发表时间：
2020-10-29
影响因子：
3.5
通讯作者：
Mao, Qiuxia
中科院分区：
文献类型：
--
作者：
Gao, Yihong;Zhu, Hongliu;Mao, Qiuxia
越来越多的证据表明长链非编码RNA（lncRNA）在肿瘤的发生和发展中起着重要作用。FGD 5反义RNA 1（FGD 5-AS 1）是一种新发现的lncRNA，它在多种肿瘤中过表达。本研究旨在探讨FGD 5-AS 1在黑色素瘤中的表达及其与黑色素瘤患者临床预后的关系。方法采用实时荧光定量PCR方法检测188对黑色素瘤标本及配对的非肿瘤标本中FGD 5-AS 1的表达水平。进行卡方检验以确定FGD 5-AS 1水平与临床病理特征之间的关系。采用Kaplan-Meier法结合log-rank检验计算基于FGD 5-AS 1表达的黑色素瘤患者的总生存率。结果FGD 5-AS 1在黑色素瘤组织中表达明显高于癌旁组织（p < 0.01），在正常组织中表达明显高于癌旁组织（p < 0.01）。在恶性病例中，FGD 5-AS 1的高表达与肿瘤厚度（p = 0.024）和晚期肿瘤分期（p = 0.039）显著相关。我们的临床研究数据显示，FGD 5-AS 1高表达患者的总生存期（p = 0.0034）和无病生存期（p < 0.0001）明显短于FGD 5-AS 1低表达患者。结论FGD 5-AS 1可能是黑色素瘤患者的一个预后预测因子和一个可能的药物靶点。
Background Growing evidence demonstrates that long non-coding RNAs (lncRNAs) play an important role in cancer origination and progression. A novel identified lncRNA, FGD5 antisense RNA 1 (FGD5-AS1), was reported to be overexpressed in several tumors. The present study aimed to investigate the expression of FGD5-AS1 in melanoma and its associations with clinical prognosis in melanoma patients.Methods The expression levels of FGD5-AS1 in 188 pairs of melanoma specimens and matched non-tumor specimens were determined using a real-time polymerase chain reaction. A chi-squared test was performed to determine the relationship between FGD5-AS1 levels and clinicopathological features. The overall survival rates of melanoma patients based on the expression of FGD5-AS1 were calculated by the Kaplan-Meier method with a log-rank test. Finally, univariate and multivariate assays were carried out to determine whether FGD5-AS1 was a prognostic factor in melanoma patients.Results We observed that FGD5-AS1 in melanoma specimens was distinctly up-regulated compared to adjacent non-tumor specimens (p < 0.01). In malignant cases, higher expression of FGD5-AS1 was prominently associated with tumor thickness (p = 0.024) and advanced tumor stage (p = 0.039). The data from our clinical study revealed that patients with high FGD5-AS1 expression had a distinctly shorter overall survival (p = 0.0034) and disease-free survival (p < 0.0001) than those with low FGD5-AS1 expression. Multivariate analysis demonstrated that high FGD5-AS1 expression may serve as a potential independent prognostic factor in melanoma.Conclusions FGD5-AS1 may act as a prognostic predictor and a possible drug-target for melanoma patients.